Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Elizabeth Smyth MD

Elizabeth Smyth MD

Consultant Medical Oncologist, Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Dr. Elizabeth (Lizzy) Smyth works as a consultant medical oncologist in upper gastrointestinal oncology at Oxford University Hospitals NHS Foundation Trust with a research focus in oesophagogastric cancer. Her interests are clinical trials and translational research, and she has worked on trial design and management of national and international investigator-initiated trials. She is committed to furthering national and international collaboration in gastrointestinal cancer research and improving outcomes for patients with oesophagogastric cancer, and to that end is very involved with EORTC efforts in gastrointestinal tract cancer. In 2022, Dr. Smyth was a founding member of the United Kingdom and Ireland Oesophagogastric Cancer Group (UKIOG), and she is a trustee of the UKIOG Charity.

Dr. Smyth has published more than 170 peer-reviewed manuscripts in her field, including in high-impact journals. She is highly active in ESMO and is the senior author of the recent ESMO Clinical Cancer Guidelines for both gastric and oesophageal cancer.

Recent Contributions to PracticeUpdate:

  1. Perioperative FOLFIRINOX for Gastroesophageal Adenocarcinoma
  2. Safety of TAS-102 in Patients With Metastatic Gastric/GE Junction and Colorectal Cancer
  3. Pembrolizumab Alone or With Chemotherapy for Advanced Gastric/GE Junction Cancer
  4. Effects of Mismatch Repair Deficiency and Microsatellite Instability on Gastric Cancer Outcomes
  5. Immunotherapy in Chemorefractory Gastric Cancer
  6. Lenvatinib for Hepatocellular Carcinoma
  7. Cabozantinib for Hepatocellular Carcinoma
  8. A Conceptual Overview of Targeted Therapy in GI Cancers
  9. ESMO 2018: TAS-102 for Refractory Metastatic Gastric Cancer
  10. ESMO 2018: Potential New Options for Patients With HER2+ Gastric Cancer

Elsewhere

Recently Updated